Long-term clinical outcomes of transient and persistent no-reflow following percutaneous coronary intervention (PCI): A multicentre Australian registry

EuroIntervention

Volumn 14, Issue 2, 2018, Pages 185-193

  Papapostolou, Stavroula ^a   Andrianopoulos, Nick ^b   Duffy, Stephen J ^a,b   Brennan, Angela L ^b   Ajani, Andrew E ^c   Clark, David J ^d   Reid, Christopher M ^e   Freeman, Melanie ^f   Sebastian, Martin ^g   Selkrig, Laura ^a   Yudi, Matias B ^d   Noaman, Samer Q ^a   Chan, William ^a,h  

^a ALFRED HOSPITAL   (Australia)

^b MONASH UNIVERSITY   (Australia)

^c ROYAL MELBOURNE HOSPITAL   (Australia)

^d AUSTIN HOSPITAL   (Australia)

^e CURTIN UNIVERSITY   (Australia)

^f EASTERN HEALTH   (Australia)

^g GEELONG HOSPITAL   (Australia)

^h UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Acute coronary syndrome Myocardial infarction Non ST elevation myocardial infarction; ST elevation myocardial infarction

Indexed keywords

ADULT; AGED; ALL CAUSE MORTALITY; ARTICLE; AUSTRALIA; CARDIOGENIC SHOCK; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR PARAMETERS; CLINICAL OUTCOME; CONTROLLED STUDY; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; INDEPENDENT VARIABLE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MORTALITY RATE; OUT OF HOSPITAL CARDIAC ARREST; PERCUTANEOUS CORONARY INTERVENTION; PREDICTOR VARIABLE; REGISTER; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION;

EID: 85049017299     PISSN: 1774024X     EISSN: 19696213     Source Type: Journal    
DOI: 10.4244/EIJ-D-17-00269     Document Type: Article

References (23)

1. Chan W, Stub D, Clark DJ, Ajani AE, Andrianopoulos N, Brennan AL, New G, Black A, Shaw JA, Reid CM, Dart AM, Duffy SJ; Melbourne Interventional Group Investigators. Usefulness of transient and persistent no reflow to predict adverse clinical outcomes following percutaneous coronary intervention. Am J Cardiol. 2012;109:478-85.
2. Ndrepepa G, Tiroch K, Fusaro M, Keta D, Seyfarth M, Byrne RA, Pache J, Alger P, Mehilli J, Schömig A, Kastrati A. 5-year prognostic value of no-reflow phenomenon after percutaneous coronary intervention in patients with acute myocardial infarction. J Am Coll Cardiol. 2010;55:2383-9.
3. Morishima I, Sone T, Okumura K, Tsuboi H, Kondo J, Mukawa H, Matsui H, Toki Y, Ito T, Hayakawa T. Angiographic no-reflow phenomenon as a predictor of adverse long-term outcome in patients treated with percutaneous transluminal coronary angioplasty for first acute myocardial infarction. J Am Coll Cardiol. 2000;36:1202-9.
4. Butler MJ, Chan W, Taylor AJ, Dart AM, Duffy SJ. Management of the no-reflow phenomenon. Pharmacol Ther. 2011; 132:72-85.
5. Jinnouchi H, Sakakura K, Wada H, Arao K, Kubo N, Sugawara Y, Funayama H, Momomura S, Ako J. Transient no reflow following primary percutaneous coronary intervention. Heart Vessels. 2014;29:429-36.
6. Brosh D, Assali AR, Mager A, Porter A, Hasdai D, Teplitsky I, Rechavia E, Fuchs S, Battler A, Kornowski R. Effect of no-reflow during primary percutaneous coronary intervention for acute myocardial infarction on six-month mortality. Am J Cardiol. 2007; 99:442-5.
7. Mehta RH, Harjai KJ, Boura J, Cox D, Stone GW, O'Neill W, Grines CL; Primary Angioplasty in Myocardial Infarction (PAMI) Investigators. Prognostic significance of transient no-reflow during primary percutaneous coronary intervention for ST-elevation acute myocardial infarction. Am J Cardiol. 2003;92:1445-7.
8. Kim MC, Cho JY, Jeong HC, Lee KH, Park KH, Sim DS, Yoon NS, Youn HJ, Kim KH, Hong YJ, Park HW, Kim JH, Jeong MH, Cho JG, Park JC, Seung KB, Chang K, Ahn Y. Long-Term Clinical Outcomes of Transient and Persistent No Reflow Phenomena following Percutaneous Coronary Intervention in Patients with Acute Myocardial Infarction. Korean Circ J. 2016;46:490-8.
9. Ajani AE, Szto G, Duffy SJ, Eccleston D, Clark DJ, Lefkovits J, Chew DP, Warren R, Black A, New G, Walton A, Lew R, Shaw J, Horrigan M, Sebastian M, Yan BP, Brennan A, Meehan A, Reid C, Krum H; Melbourne Interventional Group investigators. The foundation and launch of the Melbourne Interventional Group: a collaborative interventional cardiology project. Heart Lung Circ. 2006;15:44-7.
10. Chan W, Clark DJ, Ajani AE, Yap CH, Andrianopoulos N, Brennan AL, Dinh DT, Shardey GC, Smith JA, Reid CM, Duffy SJ. Progress towards a National Cardiac Procedure Database-development of the Australasian Society of Cardiac and Thoracic Surgeons (ASCTS) and Melbourne Interventional Group (MIG) registries. Heart Lung Circ. 2011;20:10-8.
11. Andrianopoulos N, Dinh D, Duffy SJ, Clark DJ, Brennan AL, Chan W, Shardey GC, Smith JA, Yap CH, Buxton BF, Ajani AE, Reid CM. Quality control activities associated with registries in interventional cardiology and surgery. Heart Lung Circ. 2011; 20:180-6.
12. Lagerqvist B, James SK, Stenestrand U, Lindbäck J, Nilsson T, Wallentin L; SCAAR Study Group. Long-term outcomes with drug-eluting stents versus bare-metal stents in Sweden. N Engl J Med. 2007;356:1009-19.
13. TIMI Study Group. Comparison of invasive and conservative strategies after treatment with intravenous tissue plasminogen activator in acute myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) phase II trial. N Engl J Med. 1989; 320:618-27.
14. Newson RB. Comparing the predictive powers of survival models using Harrell's C or Somers' D. Stata Journal. 2010;10: 339-58.
15. Harrison RW, Aggarwal A, Ou FS, Klein LW, Rumsfeld JS, Roe MT, Wang TY; American College of Cardiology National Cardiovascular Data Registry. Incidence and outcomes of no-reflow phenomenon during percutaneous coronary intervention among patients with acute myocardial infarction. Am J Cardiol. 2013;111:178-84.
16. Mazhar J, Mashicharan M, Farshid A. Predictors and outcome of no-reflow post primary percutaneous coronary intervention for ST elevation myocardial infarction. Int J Cardiol Heart Vasc. 2015;10:8-12.
17. Jaffe R, Charron T, Puley G, Dick A, Strauss BH. Microvascular obstruction and the no-reflow phenomenon after percutaneous coronary intervention. Circulation. 2008;117: 3152-6.
18. Niccoli G, Burzotta F, Galiuto L, Crea F. Myocardial no-reflow in humans. J Am Coll Cardiol. 2009;54:281-92.
19. Yang L, Mu L, Sun L, Qi F, Guo R. Effect of intracoronary nitroprusside injection on flow recovery during primary PCI in acute STEMI patients. Minerva Cardioangiol. 2017;65:111-8.
20. Zhao YJ, Fu XH, Ma XX, Wang DY, Dong QL, Wang YB, Li W, Xing K, Gu XS, Jiang YF. Intracoronary fixed dose of nitroprusside via thrombus aspiration catheter for the prevention of the no-reflow phenomenon following primary percutaneous coronary intervention in acute myocardial infarction. Exp Ther Med. 2013;6:479-84.
21. Ibanez B, Heusch G, Ovize M, Van de Werf F. Evolving therapies for myocardial ischemia/reperfusion injury. J Am Coll Cardiol. 2015;65:1454-71.
22. Zhao JL, Yang YJ, Pei WD, Sun YH, Chen JL. The effect of statins on the no-reflow phenomenon: an observational study in patients with hyperglycemia before primary angioplasty. Am J Cardiovasc Drugs. 2009;9:81-9.
23. Niccoli G, Cosentino N, Spaziani C, Fracassi F, Tarantini G, Crea F. No-reflow: incidence and detection in the cath-lab. Curr Pharm Des. 2013;19:4564-75.